Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension
A legfontosabb adatok
- Ki végzi
- The First Affiliated Hospital with Nanjing Medical University
- Hol
- Kína3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 103 fő vett részt
- Kezdés
- 2021. nov. 1.
- Befejezés
- 2023. nov. 20.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- focused power ultrasound mediate inferior perirenal adipose tussue modification
- sham-control group
- A regiszteradat frissítve
- 2023. december 7.
- Miért állt le
- Till interim analysis, 100 cases were enrolled, 71 of which during the COVID-19. Affected by epidemic control policy, 58 cases had examination window exceeded or missed, causing significant impact on endpoints, so we decided to terminate the trial.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Individual has office systolic blood pressure (SBP) ≥ 140 mmHg and <180 mmHg when receiving a medication regimen of one, two, or three antihypertensive medication classes;
- Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥135 mmHg;
- The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm;
- Individual is willing to sign the informed consent of the study
Ki nem vehet részt
- Individual is diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome);
- Individual has history of kidney and or kidney surrounding tissue surgery
- Individual has myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment
- Individual has type 1 diabetes or poorly-controlled type 2 diabetes;
- Individual has severe structural heart disease (e.g. heart valve disease, cardiomyopathy, congenital heart disease)
- Individual has infected waist skin
- Individual has malignant tumor
- Individuals has impairment of liver or kidney function (ALT, AST or creatinine is greater than 2 times of the upper limit of normal reference)
- Individual has uncontrolled thyroid dysfunction
- Individual has urinary calculi and/or hematuria;
- Individual has atrial fibrillation
- Individual has second degree and above atrioventricular block;
- Individual has abnormal coagulation function
- Individual is pregnant, nursing or planning to be pregnant
- Individual is unwilling to sign informed consent
- Individual fails to complete the screening period
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This randomized, double blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.
A vizsgálat 2 csoportja
- intervention groupA vizsgált kezelés
In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
Kezelés: focused power ultrasound mediate inferior perirenal adipose tussue modification
- sham-control groupSzínlelt kezelés, összehasonlításként
In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: a Multicenter, Randomized, Double-blinded Controlled Trial. PARADISE Study
- Publikációk
- A regiszteradat frissítve
- 2023. december 7.